Results 231 to 240 of about 774,346 (269)

Branched Neurotensin for Tumor Targeting

2010
Introduction One of the major problems in classic chemotherapy is the non-specific toxicity of most anticancer agents against normal cells. The specific targeting of tumors has been the main challenge in research on cancer therapy and diagnosis.
FALCIANI C., FABRINI M., LELLI B., LOZZI L., PINI A., BRACCI L.   +5 more
openaire   +3 more sources

Targeting Tumor Lymphangiogenesis: An Update

Current Medicinal Chemistry, 2010
Various human tumors preferentially metastasize by lymphatic route and lymphovascular invasion predicts lymph node metastasis. In this review article, we will summarize recent literature data concerning lymphangiogenesis, focusing on tumor lymphangiogenesis.
RAICA M, RIBATTI, Domenico
openaire   +2 more sources

Targeting of the tumor microenvironment by curcumin

BioFactors, 2021
AbstractThe tumor microenvironment (TME) is made up of several cells and molecules that affect the survival of cancer cells. Indeed, certain (immunosuppressive) cells which promote tumors can promote the growth of tumors by stimulating the proliferation of cancer cells and promoting angiogenesis.
Xiao Fu, Yingni He, Mu Li, Zezhi Huang, Masoud Najafi   +4 more
openaire   +2 more sources

p62 as a therapeutic target for tumor

European Journal of Medicinal Chemistry, 2020
p62/SQSTM1 (hereafter as p62) is a stress-inducible cellular protein, which interacts with various signaling proteins to regulate a variety of cellular functions. Growing lines of evidence supported a critical role of p62 in tumorigenesis, and p62 may become a therapeutic target for tumor. In this review, we summarize biological functions of structural
Mengmin, Tao, Tian, Liu, Qidong, You, Zhengyu, Jiang   +3 more
openaire   +2 more sources

Targeted Tumor Therapies at a Glance

Current Drug Targets, 2009
Conventional tumor therapy is usually based on surgery, radiation and chemotherapy. Treatment with chemotherapeutics is often impeded by dose-limiting toxicities. Therefore, medical scientists sought for tools to improve chemotherapy by directly coupling targeting molecules to cytotoxic substances.
H, Fuchs, C, Bachran
openaire   +2 more sources

Fibronectin as target for tumor therapy

International Journal of Cancer, 2005
During cancer progression, the extracellular matrix (ECM) of the tissue in which the tumor grows is extensively remodeled, both by degradation of preexisting ECM molecules and by the neosynthesis of ECM components, which in many cases are not present in the ECM of normal tissues. Fibronectin (FN), a class of high-molecular-weight adhesive glycoproteins,
Kaspar M, Zardi L, Neri D
openaire   +3 more sources

Tumor‐Targeted Catalytic Immunotherapy

Advanced Materials
Abstract Cancer immunotherapy holds significant promise for improving cancer treatment efficacy; however, the low response rate remains a considerable challenge. To overcome this limitation, advanced catalytic materials offer potential in augmenting catalytic immunotherapy by modulating the immunosuppressive tumor microenvironment ...
En‐Li Yang, Wu‐Yin Wang, Ying‐Qi Liu, Hong Yi, Aiwen Lei, Zhi‐Jun Sun   +5 more
openaire   +2 more sources

Tumor Stroma as a Target in Cancer

Current Cancer Drug Targets, 2008
Solid tumors are composed of the malignant cell itself (most commonly a carcinoma) and supporting cells that comprise the stroma. Significant stromal components include the extracellular matrix, supporting fibroblasts, vessels comprised of endothelium, pericytes and in some cases vascular smooth muscle, lymphatics and usually a major leukocyte ...
F, Ahmed, J C, Steele, J M J, Herbert, N M, Steven, R, Bicknell   +4 more
openaire   +2 more sources

Immunotherapy of tumor by targeting angiogenesis

Science in China Series C, 2004
Tumor growth and metastasis are angiogenesis-dependent. Anti-angiogenic therapy represents a new strategy for the development of anti-cancer therapies. In recent years, there has been made great progress in anti-angiogenic therapy. As far as the passive immunotherapy is concerned, a recombinant humanized antibody to vascular endothelial growth factor ...
Jianmei, Hou, Ling, Tian, Yuquan, Wei
openaire   +2 more sources

Targeting Tumors

Cancer remains a global health challenge, with conventional treatments often limited by toxicity and specificity. Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized cancer treatment by modifying T cells to target tumor antigens, showing significant success in hematological malignancies like acute lymphoblastic leukemia and diffuse large ...
Safiya Mehraj, Shazia Ali
openaire   +1 more source